Gold standard clinical trial in healthy UK adultsUpdated 10 days ago
What did the UK's first double-blind, placebo-controlled RCT on a multivitamin reveal about Vitals⁺?
As part of our commitment to the highest standard of clinical evidence, Vitals⁺ was put through the first UK-based double-blind, placebo-controlled randomised controlled trial of a multivitamin in healthy adults.
🔬 What was the setup?
37 healthy UK adults (mean age 29, no diagnosed medical conditions or micronutrient deficiencies) took either Vitals⁺ or an identical placebo daily for 12 weeks. Fasted blood samples were taken before and after the intervention to measure nutrient biomarkers, alongside routine safety testing.
🤔 What did they discover?
Hidden deficiencies were common, even in healthy people
Despite being an apparently healthy group, 40% were deficient in folate (B9), 34% in vitamin B12, and 83% had suboptimal riboflavin (B2) levels. Over half also showed elevated homocysteine — a metabolic marker linked to cardiovascular and brain health.
Significant improvements in key biomarkers
After 12 weeks, Vitals⁺ produced statistically significant improvements compared to placebo:
- Folate (B9) up by 82%
- Vitamin B6 up by 115%
- Vitamin B12 up by 25%
- Riboflavin (B2) improved by 17%
- Homocysteine levels down by 33%
Clinically confirmed safe
Routine safety testing found no meaningful differences between Vitals⁺ and placebo across liver, kidney, and blood health markers. Vitals⁺ was well tolerated with no significant safety concerns reported.
💡 Why does this matter?
This trial shows that even people who consider themselves healthy are often falling short on key nutrients — and that Vitals⁺ can meaningfully correct those gaps. The gold-standard RCT design means these results are among the most rigorous evidence available for any multivitamin on the market.
